Speakers | Kisaco Research

Speakers

Life Sciences Strategy Summit on IP & Exclusivity
7-8 October, 2025
Munich, Germany

Our 60+ executive speaking faculty, armed with their industry experience, war stories and more, are here to help you demystify the legal IP landscape and strengthen your exclusivity strategies

 

DOWNLOAD THE EVENT AGENDA AND SEE WHAT SESSION EACH SPEAKER IS ON 


If you wish to get involved, contact [email protected] for further information
  • Author:

    Adrian Chew

    Of Counsel
    Bristows

    Adrian Chew

    Of Counsel
    Bristows
  • Author:

    Adrian Spillmann

    Director of Intellectual Property
    Valneva

    Adrian Spillmann

    Director of Intellectual Property
    Valneva
  • Author:

    Agathe Michel-De-Cazotte

    Partner
    Carpmaels & Ransford

    Agathe Michel-De-Cazotte

    Partner
    Carpmaels & Ransford
  • Author:

    Agnieszka Deeg-Tyburska

    General Counsel
    Polpharma

    Agnieszka Deeg-Tyburska

    General Counsel
    Polpharma
  • Author:

    Ana Lopez Lozano

    Lead Patent Counsel
    Zentiva

    Ana Lopez Lozano

    Lead Patent Counsel
    Zentiva
  • Author:

    Andre Andrade

    Vice President, Client Relations EMEA and Law Firms,
    RWS

    Andre Andrade

    Vice President, Client Relations EMEA and Law Firms,
    RWS
  • Author:

    Andreas Robinson

    Senior Counsel Intellectual Property & Litigation
    Amgen

    Andreas Robinson

    Senior Counsel Intellectual Property & Litigation
    Amgen
  • Author:

    Anna Wolters-Hoehne

    Partner
    A & O Shearman

    Anna is a highly experienced patent litigator advising primarily life sciences clients in global patent disputes. With about 20 years of practice in leading and coordinating high profile patent cases Anna develops both offensive and defensive patent strategies for her clients to protect their product portfolio nationally and in an international context.

    Anna’s long-standing expertise covers patent infringement and preliminary injunction proceedings as well as patent damages proceedings before the German courts. She also advises on national compulsory licence cases and nullity actions as well as EPO opposition proceedings and the UPC. Anna regularly coordinates international patent disputes and advises clients in particular from the innovative pharmaceutical and medical device industries. 

    Anna Wolters-Hoehne

    Partner
    A & O Shearman

    Anna is a highly experienced patent litigator advising primarily life sciences clients in global patent disputes. With about 20 years of practice in leading and coordinating high profile patent cases Anna develops both offensive and defensive patent strategies for her clients to protect their product portfolio nationally and in an international context.

    Anna’s long-standing expertise covers patent infringement and preliminary injunction proceedings as well as patent damages proceedings before the German courts. She also advises on national compulsory licence cases and nullity actions as well as EPO opposition proceedings and the UPC. Anna regularly coordinates international patent disputes and advises clients in particular from the innovative pharmaceutical and medical device industries. 

  • Author:

    Axel Berger

    Partner
    Bardehle

    Axel Berger

    Partner
    Bardehle
  • Author:

    Betsy Flanagan

    Partner
    Cooley

    Betsy Flanagan

    Partner
    Cooley
  • Author:

    Bianca Vos

    Partner
    Hoffmann Eitle

    Bianca Vos

    Partner
    Hoffmann Eitle
  • Author:

    Boris Andrejas

    Case Handler
    DG Comp

    Boris Andrejas

    Case Handler
    DG Comp
  • Author:

    Brian Coggio

    Counsel
    Fish & Richardson

    Brian Coggio

    Counsel
    Fish & Richardson
  • Author:

    Cecile Teles

    Head of IP
    Zentiva

    Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry.

    Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house at an elite innovator company (Sanofi), biologics (Merck Serono), and extensive generic experience she gained as Zentiva.

    Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi.

    Cecile is a qualified European Patent Attorney. She also holds a certificate from CEIPI in patent litigation and most recently completed her diploma as a Master of Laws in France.

    Cecile Teles

    Head of IP
    Zentiva

    Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry.

    Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house at an elite innovator company (Sanofi), biologics (Merck Serono), and extensive generic experience she gained as Zentiva.

    Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi.

    Cecile is a qualified European Patent Attorney. She also holds a certificate from CEIPI in patent litigation and most recently completed her diploma as a Master of Laws in France.

  • Author:

    Charlotte Weekes

    Partner
    Pinsent Masons

    Charlotte Weekes

    Partner
    Pinsent Masons
  • Author:

    Christina Brown-Marshall

    Principal
    Fish & Richardson

    Christina Brown-Marshall

    Principal
    Fish & Richardson
  • Author:

    Christina Thomson

    Managing Associate
    Simmons & Simmons

    Christina Thomson

    Managing Associate
    Simmons & Simmons
  • Author:

    Christof Bull

    Associate General Patent Counsel
    UCB

    Christof Bull

    Associate General Patent Counsel
    UCB
  • Author:

    Christoph Rehfuess

    Head of IP
    Sotio

    Christoph Rehfuess

    Head of IP
    Sotio
  • Author:

    Claudia Milbradt

    Partner
    Clifford Chance

    Claudia Milbradt

    Partner
    Clifford Chance
  • Author:

    Corinna Sundermann

    Senior Vice President Intellectual Property
    Fresenius Kabi

    Corinna Sundermann

    Senior Vice President Intellectual Property
    Fresenius Kabi
  • Author:

    Denis Schertenleib

    Partner
    Schertenleib Avocats

    Denis Schertenleib

    Partner
    Schertenleib Avocats
  • Author:

    Dolores Cassidy

    Head of Patent/SPC Examination
    Intellectual Property Office of Ireland

    Dolores Cassidy, B.Sc. Ph.D., graduated from University College Dublin with a Ph.D. in Physical Chemistry.  In 1998 she joined the Intellectual Property Office of Ireland as a Patent Examiner, with particular responsibility for the examination of Supplementary Protection Certificates (SPCs).  In 2021 she was promoted to the position of Head of Patent/SPC Examination at the Irish Office.

    Dolores Cassidy

    Head of Patent/SPC Examination
    Intellectual Property Office of Ireland

    Dolores Cassidy, B.Sc. Ph.D., graduated from University College Dublin with a Ph.D. in Physical Chemistry.  In 1998 she joined the Intellectual Property Office of Ireland as a Patent Examiner, with particular responsibility for the examination of Supplementary Protection Certificates (SPCs).  In 2021 she was promoted to the position of Head of Patent/SPC Examination at the Irish Office.

  • Author:

    Dorian Immler

    Head of Patents
    Bayer

    Dorian Immler

    Head of Patents
    Bayer
  • Author:

    Eduardo Hallak

    Partner
    Licks Attorney

    Eduardo Hallak is one of the founding partners at Licks Attorneys and one of our leaders at the Sao Paulo office. For more than a decade, he has been working as a litigator before state and federal courts in Brazil in several complex disputes and leading cases involving Patent law, competition, and regulatory compliance, most of them pursuing the interests of clients in the area of life sciences. He also has extensive practice in trademark litigation as well as technology transfer contracts, working together with multinational clients to establish strong brand protection and licensing programs in the country. Mr. Hallak also currently teaches IP litigation in the Post-Graduation course at the prestigious Pontifical Catholic University of Rio de Janeiro (PUCRJ), has taught Civil Procedure at the at the Brazilian Association of IP Agents (ABAPI), and is often invited to lecture on procedural and strategic aspects of IP litigation, in addition to being a member of the Special Commission on Mediation of the Rio de Janeiro Chapter of the Brazilian Bar Association (OABRJ) and the Enforcement Committee of INTA.

    Eduardo Hallak

    Partner
    Licks Attorney

    Eduardo Hallak is one of the founding partners at Licks Attorneys and one of our leaders at the Sao Paulo office. For more than a decade, he has been working as a litigator before state and federal courts in Brazil in several complex disputes and leading cases involving Patent law, competition, and regulatory compliance, most of them pursuing the interests of clients in the area of life sciences. He also has extensive practice in trademark litigation as well as technology transfer contracts, working together with multinational clients to establish strong brand protection and licensing programs in the country. Mr. Hallak also currently teaches IP litigation in the Post-Graduation course at the prestigious Pontifical Catholic University of Rio de Janeiro (PUCRJ), has taught Civil Procedure at the at the Brazilian Association of IP Agents (ABAPI), and is often invited to lecture on procedural and strategic aspects of IP litigation, in addition to being a member of the Special Commission on Mediation of the Rio de Janeiro Chapter of the Brazilian Bar Association (OABRJ) and the Enforcement Committee of INTA.

  • Author:

    Elodie Ferraty

    Head of Chemistry Division
    INPI

    Elodie Ferraty

    Head of Chemistry Division
    INPI
  • Author:

    Eva Ehlich

    Partner
    Maiwald

    Eva Ehlich

    Partner
    Maiwald
  • Author:

    Filipe Pedro

    Director of IP
    BIAL

    Filipe Pedro

    Director of IP
    BIAL
  • Author:

    Florian Bechtel

    Senior Counsel- Digital & Device IP
    Sanofi

    Florian Bechtel

    Senior Counsel- Digital & Device IP
    Sanofi
  • Author:

    Fritz Gerritzen

    Partner
    A & O Shearman

    Fritz Gerritzen

    Partner
    A & O Shearman
  • Author:

    Gemma Barrett

    Partner
    A & O Shearman

    Gemma is an experienced and trusted advisor for some of the world’s leading life sciences and chemical companies. Her background in biochemistry means she specialises in complex technical disputes in the life sciences sector.  She has more than fifteen years’ experience advising clients in patent litigation matters before the English Courts including securing preliminary injunctions. She is also experienced in advising on global cross-border litigation, and coordinating worldwide litigation, working closely with multi-disciplinary teams in the defence and enforcement of patent portfolios. She has developed innovative and successful strategies, often combining patent and regulatory law, to assist pharmaceutical companies in the enforcement of their rights.

    Gemma Barrett

    Partner
    A & O Shearman

    Gemma is an experienced and trusted advisor for some of the world’s leading life sciences and chemical companies. Her background in biochemistry means she specialises in complex technical disputes in the life sciences sector.  She has more than fifteen years’ experience advising clients in patent litigation matters before the English Courts including securing preliminary injunctions. She is also experienced in advising on global cross-border litigation, and coordinating worldwide litigation, working closely with multi-disciplinary teams in the defence and enforcement of patent portfolios. She has developed innovative and successful strategies, often combining patent and regulatory law, to assist pharmaceutical companies in the enforcement of their rights.

  • Author:

    Geoff Biegler

    Partner
    Cooley

    Geoff Biegler

    Partner
    Cooley
  • Author:

    Ha Kung Wong

    Partner, Advisory Board Member
    Venable, Centre for Biosimilars

    Ha Kung Wong has over 20 years of experience practicing general intellectual property law with an emphasis on complex patent and trade secret litigation as well as IP transactions and contract negotiations for mergers, acquisitions, and collaborations in pharmaceuticals, biologics, and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, allergy eye drops, anti-epileptic drugs, anti-tussive, injectable microspheres, RNAi products, and other pharmaceuticals. Mr. Wong also has extensive experience with Inter Partes Review, Post Grant Review, intellectual property counseling, pharmaceutical regulatory counseling, pre-suit investigations, licensing, and due diligence.

    Mr. Wong has his BS with high distinction in Chemistry and his BS in Biochemistry from the University of Illinois Urbana-Champaign and his JD, cum laude, from the University of Notre Dame. Mr. Wong is currently an elected member of the Venable Board, is an Advisory Board Member for the Center for Biosimilars, is Treasurer, Executive Committee member, and Board Trustee for the Foundation for Advancement of Diversity in IP Law (FADIPL) and serves as faculty for the National Institute of Trial Advocacy (NITA) and Lawline.

    Ha Kung Wong

    Partner, Advisory Board Member
    Venable, Centre for Biosimilars

    Ha Kung Wong has over 20 years of experience practicing general intellectual property law with an emphasis on complex patent and trade secret litigation as well as IP transactions and contract negotiations for mergers, acquisitions, and collaborations in pharmaceuticals, biologics, and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, allergy eye drops, anti-epileptic drugs, anti-tussive, injectable microspheres, RNAi products, and other pharmaceuticals. Mr. Wong also has extensive experience with Inter Partes Review, Post Grant Review, intellectual property counseling, pharmaceutical regulatory counseling, pre-suit investigations, licensing, and due diligence.

    Mr. Wong has his BS with high distinction in Chemistry and his BS in Biochemistry from the University of Illinois Urbana-Champaign and his JD, cum laude, from the University of Notre Dame. Mr. Wong is currently an elected member of the Venable Board, is an Advisory Board Member for the Center for Biosimilars, is Treasurer, Executive Committee member, and Board Trustee for the Foundation for Advancement of Diversity in IP Law (FADIPL) and serves as faculty for the National Institute of Trial Advocacy (NITA) and Lawline.

  • Author:

    Hilary Pioro

    Senior Patent Counsel
    Polpharma Biologics

    Hilary Pioro

    Senior Patent Counsel
    Polpharma Biologics
  • Author:

    Isabelle Gundel

    Senior Patent Attorney
    Haleon

    Isabelle Gundel

    Senior Patent Attorney
    Haleon
  • Author:

    Isobel Barry

    Partner
    Carpmaels & Ransford

    Isobel Barry

    Partner
    Carpmaels & Ransford
  • Author:

    James Horgan

    Chief IP Counsel
    MSD

    James Horgan

    Chief IP Counsel
    MSD
  • Author:

    Jiri Slavik

    Director of IP
    Adalvo

    Jiri Slavik

    Director of IP
    Adalvo
  • Author:

    Judith Krens

    Partner
    Pinsent Masons

    Judith Krens

    Partner
    Pinsent Masons
  • Author:

    Julia Pike

    Global Head of IP
    Sandoz

    Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.

     

    Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world. 

    Julia Pike

    Global Head of IP
    Sandoz

    Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.

     

    Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world. 

  • Author:

    Karin Pramberger

    Head of IP
    Polpharma Group

    Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva.  She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam. 

    Karin Pramberger

    Head of IP
    Polpharma Group

    Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva.  She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam. 

  • Author:

    Katherine Helm

    Partner
    Dechert

    Katherine Helm

    Partner
    Dechert
  • Author:

    Katie Rooth

    Lead IP Litigation Counsel
    Sandoz

    Katie Rooth

    Lead IP Litigation Counsel
    Sandoz
  • Author:

    Kaushal Joshi

    Senor Director Legal, IP and Product Portfolio
    Kashiv Biosciences

    Kaushal Joshi

    Senor Director Legal, IP and Product Portfolio
    Kashiv Biosciences
  • Author:

    Kora Knuchel

    Vice President, IP & Legal
    Bruker

    Kora Knuchel

    Vice President, IP & Legal
    Bruker
  • Author:

    Laila Beynon

    AD- Dispute Resolution
    Regeneron

    Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT. 

    Laila Beynon

    AD- Dispute Resolution
    Regeneron

    Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT. 

  • Author:

    Lora Green

    Partner
    Gemini Law

    Prior to joining Gemini, Lora was a senior partner at Wilson, Sonsini, Goodrich & Rosati, as part of the firm’s PTAB practice group.
    Before entering private practice, Lora was a Lead Administrative Patent Judge at the U.S. Patent & Trademark Office, as well as a primary patent examiner in the pharmaceutical and biotechnology examining groups. While at the USPTO, she managed post-grant review proceedings, such as inter partes and post grant reviews.

    Lora Green

    Partner
    Gemini Law

    Prior to joining Gemini, Lora was a senior partner at Wilson, Sonsini, Goodrich & Rosati, as part of the firm’s PTAB practice group.
    Before entering private practice, Lora was a Lead Administrative Patent Judge at the U.S. Patent & Trademark Office, as well as a primary patent examiner in the pharmaceutical and biotechnology examining groups. While at the USPTO, she managed post-grant review proceedings, such as inter partes and post grant reviews.

  • Author:

    Manja Epping

    Partner
    Taylor Wessing

    As a lawyer specialising in pharmaceutical and IP law, Manja has been advising pharmaceutical and biotechnology companies, medical device manufacturers, and food producers on all matters relating to intellectual property and regulatory questions for many years. One of her areas of expertise is regulatory data and market protection as well as orphan drug exclusivity, where she has a track record of representing clients before German and EU courts. Another focus of her practice involves advising clients on complex contractual projects, in particular, research and development cooperations, manufacturing agreements, distribution agreements and licence agreements.

    Manja Epping

    Partner
    Taylor Wessing

    As a lawyer specialising in pharmaceutical and IP law, Manja has been advising pharmaceutical and biotechnology companies, medical device manufacturers, and food producers on all matters relating to intellectual property and regulatory questions for many years. One of her areas of expertise is regulatory data and market protection as well as orphan drug exclusivity, where she has a track record of representing clients before German and EU courts. Another focus of her practice involves advising clients on complex contractual projects, in particular, research and development cooperations, manufacturing agreements, distribution agreements and licence agreements.

  • Author:

    Marco Stief

    Partner
    Maiwald

    Marco Stief

    Partner
    Maiwald
  • Author:

    Margaret O'Gara

    Director of IP
    Nanobiotix

    Margaret is a French and European patent attorney currently heading IP at a late development stage biotech in Paris, called Nanobiotix.

    She started her professional career as a researcher in the pharma industry in the UK and France, before moving into patents in 2004.

    Since then she has worked both in-house and in IP firms and spent nearly ten years with Santarelli before taking the IP position at Nanobiotix early 2020. Margaret has considerable experience in all aspects of European patent prosecution, and post grant proceedings, as well as strategies for filing new applications . She is interested in data exclusivity and prolonging the protection of innovative products.

    Margaret O'Gara

    Director of IP
    Nanobiotix

    Margaret is a French and European patent attorney currently heading IP at a late development stage biotech in Paris, called Nanobiotix.

    She started her professional career as a researcher in the pharma industry in the UK and France, before moving into patents in 2004.

    Since then she has worked both in-house and in IP firms and spent nearly ten years with Santarelli before taking the IP position at Nanobiotix early 2020. Margaret has considerable experience in all aspects of European patent prosecution, and post grant proceedings, as well as strategies for filing new applications . She is interested in data exclusivity and prolonging the protection of innovative products.

  • Author:

    Maria Lamottke

    VP Business Development
    Biocoll

    Maria Lamottke

    VP Business Development
    Biocoll
  • Author:

    Marius-Benjamin Schneider

    Head of Legal
    Insempra

    Marius-Benjamin Schneider

    Head of Legal
    Insempra
  • Author:

    Dr Martijn de Lange

    Patent Examiner
    Netherlands Patent Office

    Dr Martijn de Lange

    Patent Examiner
    Netherlands Patent Office
  • Author:

    Martin Schmidt

    Life Science Technical Judge
    UPC

    Martin Schmidt

    Life Science Technical Judge
    UPC
  • Author:

    Max Haedicke

    Honourable Judge
    Paris Central Division

    Max Haedicke

    Honourable Judge
    Paris Central Division
  • Author:

    Michal Porubsky

    Senior Litigation Counsel
    Novo Nordisk

    Michal Porubsky

    Senior Litigation Counsel
    Novo Nordisk
  • Author:

    Mortiz Ammelberg

    Principal
    Fish & Richardson

    Mortiz Ammelberg

    Principal
    Fish & Richardson
  • Author:

    Nicholas Mitrokostas

    Partner
    A & O Shearman

    Nick is the Managing Partner of the Boston office and an experienced Life Sciences trial attorney who focuses on representing innovator companies in intellectual property, trade secret, licensing and antitrust disputes. A litigator known for his trial skills, Nick has been lead counsel and gone to trial in dozens of ANDA and BPCIA litigations and has extensive experience representing clients in the pharmaceutical, biotechnology, and medical device industries in federal and state courts as well as before the Patent Trial and Appeal Board (PTAB).  Nick also has expertise in counseling emerging and small and mid-cap Life Sciences companies in late stage drug development on issues pertaining to patent and regulatory exclusivities including patent term extension (PTE), patent listing requirements, and pre-commercial and launch assessments and litigation risks. 

    Nicholas Mitrokostas

    Partner
    A & O Shearman

    Nick is the Managing Partner of the Boston office and an experienced Life Sciences trial attorney who focuses on representing innovator companies in intellectual property, trade secret, licensing and antitrust disputes. A litigator known for his trial skills, Nick has been lead counsel and gone to trial in dozens of ANDA and BPCIA litigations and has extensive experience representing clients in the pharmaceutical, biotechnology, and medical device industries in federal and state courts as well as before the Patent Trial and Appeal Board (PTAB).  Nick also has expertise in counseling emerging and small and mid-cap Life Sciences companies in late stage drug development on issues pertaining to patent and regulatory exclusivities including patent term extension (PTE), patent listing requirements, and pre-commercial and launch assessments and litigation risks. 

  • Author:

    Dr Oliver Werner

    Head Patent Department, Head SPC Working Group
    German Patent and Trade Mark Office

    Dr Oliver Werner

    Head Patent Department, Head SPC Working Group
    German Patent and Trade Mark Office
  • Author:

    Patrick Heckeler

    Partner
    Bardehle

    Patrick Heckeler

    Partner
    Bardehle
  • Author:

    Paul Calvo

    Director
    Sterne Kessler

    Paul Calvo

    Director
    Sterne Kessler
  • Author:

    Pedro Roman

    IP Counsel
    Insud Pharma

    Pedro Roman

    IP Counsel
    Insud Pharma
  • Author:

    Petra Bohanec Grabar

    IP Lead
    Sandoz

    Petra Bohanec Grabar is a Slovenian and European Patent Attorney and holds a diploma of Patent Litigation in Europe from the University of Strasbourg.

    Petra has extensive experience working in house. In her current role as Group Head in Sandoz, Petra leads a team of patent practitioners supporting development, in licensing and launch of generic products on global markets.

    Petra holds a PhD in Biochemistry and Molecular Biology from the Faculty of Medicine, University of Ljubljana and is an author of twelve peer reviewed articles in the field of pharmacogenetics.

    Petra Bohanec Grabar

    IP Lead
    Sandoz

    Petra Bohanec Grabar is a Slovenian and European Patent Attorney and holds a diploma of Patent Litigation in Europe from the University of Strasbourg.

    Petra has extensive experience working in house. In her current role as Group Head in Sandoz, Petra leads a team of patent practitioners supporting development, in licensing and launch of generic products on global markets.

    Petra holds a PhD in Biochemistry and Molecular Biology from the Faculty of Medicine, University of Ljubljana and is an author of twelve peer reviewed articles in the field of pharmacogenetics.

  • Author:

    Roberto Romandini

    Legal Member of the Board of Appeal
    EPO

    Roberto Romandini obtained his law degree from the University of Pisa and his LL.M. degree from the University of Munich, where he specialized in patent law. He completed his Ph.D. thesis on the patentability of human stem cells at the Max Planck Institute in Munich before practicing IP law at a leading IP law firm in Milan for 5 years. From 2013 he was a Senior Research Fellow at the Max Planck Institute for Innovation and Competition in Munich.  Since 2019 he has been a legal member at the Boards of Appeal at the EPO. 

    Roberto Romandini

    Legal Member of the Board of Appeal
    EPO

    Roberto Romandini obtained his law degree from the University of Pisa and his LL.M. degree from the University of Munich, where he specialized in patent law. He completed his Ph.D. thesis on the patentability of human stem cells at the Max Planck Institute in Munich before practicing IP law at a leading IP law firm in Milan for 5 years. From 2013 he was a Senior Research Fellow at the Max Planck Institute for Innovation and Competition in Munich.  Since 2019 he has been a legal member at the Boards of Appeal at the EPO. 

  • Author:

    Robin Ellis

    Partner
    Reddie&Grose

    Robin Ellis

    Partner
    Reddie&Grose
  • Author:

    Sabine Klepsch

    Honourable Judge
    UPC Local Division Hamburg

    Sabine Klepsch

    Honourable Judge
    UPC Local Division Hamburg
  • Author:

    Sara Burghart

    Senior Counsel- Patent Litigation
    BAT

    Sara Burghart

    Senior Counsel- Patent Litigation
    BAT
  • Author:

    Sherry Yao

    Partner
    King & Wood Mallesons

    Sherry Yao

    Partner
    King & Wood Mallesons
  • Author:

    Stefania Bergia

    Partner
    Simmons

    Stefania Bergia

    Partner
    Simmons
  • Author:

    Stefanie Kies

    Senior Director Intellectual Property
    Polpharma Biologics

    Stefanie Kies

    Senior Director Intellectual Property
    Polpharma Biologics
  • Author:

    Stephen Reese

    Partner
    Clifford Chance

    Stephen Reese

    Partner
    Clifford Chance
  • Author:

    Suzanne Renes

    European Patent Attorney
    Sanofi

    Suzanne graduated Cum Laude from Amsterdam University College in 2015 with a BSc in Biomedical Sciences. In 2016 she graduated from University College London with an MSc in Pharmaceutical Formulation and Entrepreneurship. She is a qualified Dutch and European Patent Attorney that started her career in the Pharma team at NLO in 2018. Since January 2022 she has been employed in the Ablynx team of Sanofi in Ghent, where she has been working as a patent attorney specializing in immunoglobulin single variable domains (camelid-derived VHH). In her free time, she enjoys learning new languages, playing badminton and dancing salsa.

    Suzanne Renes

    European Patent Attorney
    Sanofi

    Suzanne graduated Cum Laude from Amsterdam University College in 2015 with a BSc in Biomedical Sciences. In 2016 she graduated from University College London with an MSc in Pharmaceutical Formulation and Entrepreneurship. She is a qualified Dutch and European Patent Attorney that started her career in the Pharma team at NLO in 2018. Since January 2022 she has been employed in the Ablynx team of Sanofi in Ghent, where she has been working as a patent attorney specializing in immunoglobulin single variable domains (camelid-derived VHH). In her free time, she enjoys learning new languages, playing badminton and dancing salsa.

  • Author:

    Tamaris Bucher

    Principal Patent Attorney
    Novartis

    Tamaris is a Principal Patent Attorney at Novartis. She has gained extensive experience in pharmaceuticals in her almost ten years at Novartis, as well as from a previous role at a patent law firm in Basel.

    She specialises in patent matters relating to antibody technology and cell & gene therapies. She has expertise in patent prosecution and SPC issues, as well as a keen interest in following legal developments in these areas.

    Tamaris is both a registered European Patent Attorney and Swiss Patent Attorney. Additionally, she has a background in Australian patent law, having completed a Master of Industrial Property at the University of Technology, Sydney.

    Tamaris Bucher

    Principal Patent Attorney
    Novartis

    Tamaris is a Principal Patent Attorney at Novartis. She has gained extensive experience in pharmaceuticals in her almost ten years at Novartis, as well as from a previous role at a patent law firm in Basel.

    She specialises in patent matters relating to antibody technology and cell & gene therapies. She has expertise in patent prosecution and SPC issues, as well as a keen interest in following legal developments in these areas.

    Tamaris is both a registered European Patent Attorney and Swiss Patent Attorney. Additionally, she has a background in Australian patent law, having completed a Master of Industrial Property at the University of Technology, Sydney.

  • Author:

    Tobias Wuttke

    Partner
    Bardehle Pagenberg

    Tobias Wuttke

    Partner
    Bardehle Pagenberg